The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.

Antibodies to DNA (anti-DNA) are the serological hallmark of systemic lupus erythematosus (SLE) and can mediate disease pathogenesis by the formation of immune complexes. Since blocking immune complex formation can attenuate disease manifestations, the effects of nucleic acid binding polymers (NABPs...

Full description

Bibliographic Details
Main Authors: Nancy A Stearns, Jaewoo Lee, Kam W Leong, Bruce A Sullenger, David S Pisetsky
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3394750?pdf=render
id doaj-04a52858cab94b828ce2937d1eff4c45
record_format Article
spelling doaj-04a52858cab94b828ce2937d1eff4c452020-11-25T02:55:55ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0177e4086210.1371/journal.pone.0040862The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.Nancy A StearnsJaewoo LeeKam W LeongBruce A SullengerDavid S PisetskyAntibodies to DNA (anti-DNA) are the serological hallmark of systemic lupus erythematosus (SLE) and can mediate disease pathogenesis by the formation of immune complexes. Since blocking immune complex formation can attenuate disease manifestations, the effects of nucleic acid binding polymers (NABPs) on anti-DNA binding in vitro were investigated. The compounds tested included polyamidoamine dendrimer, 1,4-diaminobutane core, generation 3.0 (PAMAM-G3), hexadimethrine bromide, and a β-cylodextrin-containing polycation. As shown with plasma from patients with SLE, NABPs can inhibit anti-DNA antibody binding in ELISA assays. The inhibition was specific since the NABPs did not affect binding to tetanus toxoid or the Sm protein, another lupus autoantigen. Furthermore, the polymers could displace antibody from preformed complexes. Together, these results indicate that NABPs can inhibit the formation of immune complexes and may represent a new approach to treatment.http://europepmc.org/articles/PMC3394750?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Nancy A Stearns
Jaewoo Lee
Kam W Leong
Bruce A Sullenger
David S Pisetsky
spellingShingle Nancy A Stearns
Jaewoo Lee
Kam W Leong
Bruce A Sullenger
David S Pisetsky
The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.
PLoS ONE
author_facet Nancy A Stearns
Jaewoo Lee
Kam W Leong
Bruce A Sullenger
David S Pisetsky
author_sort Nancy A Stearns
title The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.
title_short The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.
title_full The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.
title_fullStr The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.
title_full_unstemmed The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.
title_sort inhibition of anti-dna binding to dna by nucleic acid binding polymers.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Antibodies to DNA (anti-DNA) are the serological hallmark of systemic lupus erythematosus (SLE) and can mediate disease pathogenesis by the formation of immune complexes. Since blocking immune complex formation can attenuate disease manifestations, the effects of nucleic acid binding polymers (NABPs) on anti-DNA binding in vitro were investigated. The compounds tested included polyamidoamine dendrimer, 1,4-diaminobutane core, generation 3.0 (PAMAM-G3), hexadimethrine bromide, and a β-cylodextrin-containing polycation. As shown with plasma from patients with SLE, NABPs can inhibit anti-DNA antibody binding in ELISA assays. The inhibition was specific since the NABPs did not affect binding to tetanus toxoid or the Sm protein, another lupus autoantigen. Furthermore, the polymers could displace antibody from preformed complexes. Together, these results indicate that NABPs can inhibit the formation of immune complexes and may represent a new approach to treatment.
url http://europepmc.org/articles/PMC3394750?pdf=render
work_keys_str_mv AT nancyastearns theinhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT jaewoolee theinhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT kamwleong theinhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT bruceasullenger theinhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT davidspisetsky theinhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT nancyastearns inhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT jaewoolee inhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT kamwleong inhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT bruceasullenger inhibitionofantidnabindingtodnabynucleicacidbindingpolymers
AT davidspisetsky inhibitionofantidnabindingtodnabynucleicacidbindingpolymers
_version_ 1724715457855881216